Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECCS 50

Drug Profile

ECCS 50

Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Plus Therapeutics; Adipose-derived stem cells - Plus Therapeutics; ADRCs - Plus Therapeutics; Cytori Cell Therapy; ECCI-50; ECCO-50; ECCS-50; Habeo; Habeo Cell Therapy

Latest Information Update: 28 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytori Therapeutics
  • Developer Aix-Marseille University; Assistance Publique - Hopitaux de Marseille; Nagoya University; Plus Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Raynaud's disease; Scleroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Scleroderma
  • No development reported Crohn's disease; Scars; Urinary incontinence

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in France (Parenteral)
  • 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Scars in Unknown
  • 06 Apr 2021 No development reported - Phase-III for Urinary incontinence in Japan (Transurethral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top